Form 4: Progyny EVP Swartz Receives Equity Grants, Executes Planned Sales

Progyny's EVP and General Counsel, Allison Swartz, reported receiving significant equity grants while also executing pre-planned sales of common stock.

Summary

• Allison Swartz, EVP, General Counsel of Progyny, Inc. (PGNY), received an annual merit grant of 28,409 Restricted Stock Units (RSUs) and 41,430 stock options on March 2, 2026.
• The RSUs and stock options will vest 33% on the first anniversary of the grant date, with the remainder vesting quarterly through the third anniversary, contingent on continued service.
• Swartz disposed of a total of 4,393 shares of common stock on March 2 and March 3, 2026, to cover withholding taxes upon RSU vesting, at prices of $17.69 and $17.60 respectively.
• Additionally, Swartz sold a total of 6,856 shares of common stock on March 2 and March 3, 2026, through a Rule 10b5-1 trading plan established on May 13, 2025, at average prices around $17.27 to $17.40.
• Following these transactions, Swartz beneficially owns 89,879 shares of common stock and 41,430 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine insider transaction report reflecting standard executive compensation practices and pre-planned stock sales, which generally indicates stability rather than significant new developments. The grants are a positive for executive alignment.

Positives

• Significant equity grants (28,409 RSUs and 41,430 stock options) demonstrate continued compensation and alignment with shareholder interests.
• The grants are part of an annual merit program, indicating ongoing performance recognition.
• The establishment of a Rule 10b5-1 trading plan on May 13, 2025, indicates pre-planned, non-discretionary sales, which is a positive governance practice.

Negatives

• Sales of common stock, even if pre-planned, reduce the insider's direct equity holding.

Future Outlook

The granted RSUs and stock options will vest over a three-year period, with 33% vesting on the first anniversary of the March 2, 2026 grant date, and the remainder vesting quarterly thereafter, subject to continued employment.

Industry Context

StockSavvy.ai notes that annual equity grants and the use of Rule 10b5-1 trading plans are standard practices for executive compensation and insider trading compliance in publicly traded companies, particularly within the healthcare or technology sectors where Progyny operates. These mechanisms aim to align executive incentives with long-term company performance while providing a structured approach for insiders to manage their equity holdings.

Comparison to Industry Standards

• The structure of equity grants with multi-year vesting schedules is consistent with industry best practices for executive retention and long-term incentive alignment, similar to programs seen at companies like Teladoc Health (TDOC) or Livongo (now part of Teladoc).
• The use of a Rule 10b5-1 plan for stock sales is a widely adopted corporate governance measure, mirroring practices at major corporations to mitigate concerns about insider trading, comparable to plans used by executives at companies such as Microsoft or Apple.

Corporate Governance

Related Party Transactions

• The reported transactions are between an executive officer (Allison Swartz) and the company (Progyny, Inc.), which are inherently related-party dealings.

Stakeholder Impact

• Shareholders: The equity grants align executive incentives with shareholder value creation. The sales, while pre-planned, represent a slight reduction in direct insider ownership.
• Employees: The annual merit grants suggest a structured compensation framework that could positively influence employee morale and retention, particularly for key personnel.

Next Steps

• Continued vesting of RSUs and stock options on their respective schedules, contingent on Allison Swartz's continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and pre-planned stock sales. While the grants are a positive for aligning executive interests, the sales are expected for tax purposes and under a 10b5-1 plan, offering no new fundamental insights into the company's performance or future prospects that would warrant a change in investment stance. It's a neutral event for the stock's valuation.

Keywords

Progyny, PGNY, Allison Swartz, Form 4, insider trading, RSU, stock options, equity grant, 10b5-1 plan, executive compensation